About this journal

Aims and scope

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.

The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary.

The journal does not accept study protocols, animal-based or cell line-based studies.

Case reports/series submitted to Therapeutics and Clinical Risk Management will be diverted to the International Medical Case Reports Journal (Journal metric data for this journal can be accessed here).

When considering submission of a paper utilizing publicly-available data (e.g. SEER), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors own data through replication in an original sample and functional follow-up.

All meta-analyses require a pre-submission check prior to submitting to Therapeutics and Clinical Risk Management. Please complete the pre-submission check form here.

Journal metrics

Usage

  • 255K annual downloads/views

Citation metrics

  • 2.3 (2023) Impact Factor
  • Q2 Impact Factor Best Quartile
  • 2.3 (2023) 5 year IF
  • 5.3 (2023) CiteScore (Scopus)
  • Q1 CiteScore Best Quartile
  • 0.963 (2023) SNIP
  • 0.752 (2023) SJR

Editorial board

Editor-in-Chief:

Professor Garry Walsh, School of Medicine, University of Aberdeen, United Kingdom

Associate Editor-in-Chief:

Professor Deyun Wang, Department of Otolaryngology, University of Singapore, Singapore

Editorial Board:

Professor Shahin Akhondzadeh, Clinical Psychopharmacology, Tehran University of Medical Sciences, Iran

Professor Guang-Yan Cai, Department of Nephrology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, China Mainland (PRC)

Dr Zhuang-Gui Chen, Pediatrics, the Third Affiliated Hospital of Sun Yat-Sen University, China Mainland (PRC)

Dr William Cho, Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, People's Republic of China. 

Mr Mark Duman, Chief Patient Officer, MD Healthcare and Co-Founder, Patient Information Forum, United Kingdom

Prof. Dr. Alfio Ferlito, Coordinator of the International Head and Neck Scientific Group, Padua, Italy

Prof. Dr. Nandu Goswami, Physiology, Medical University of Graz, Austria

Dr Howard Greenberg, Thomas Jefferson University, United States

Prof. Dr. Mihajlo Jakovljevic, Health Economics, Institute of Comparative Economic Studies, Hosei University, Tama Campus, Tokyo, Japan

Dr Faustino Ram Perez-Lopez, Obstetrics and Gynecology, University of Zaragoza Hospital Clínico, Zaragoza, Spain

Prof. Dr. Leopoldo Spadea, Department of Sensory Organs, Eye Clinic, Eye Clinic, Policlinico Umberto 1, Sapienza University of Rome, Italy

Professor Allan Spigelman, Surgery, University of New South Wales, Sydney, Australia

Professor Guglielmo Trovato, Medicine, University of Catania, Italy

Professor Scott Waldman, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA

Dr Qintai Yang, Department of Otolaryngology-Head and Neck Surgery, Third Affiliated Hospital of Sun Yat-sen University, China Mainland (PRC)

Abstracting and indexing

Therapeutics and Clinical Risk Management is indexed/tracked/covered by the following services:

Current Contents®/Clinical Medicine

Directory of Open Access Journals (DOAJ)

EMBASE (Elsevier)

ICAAP

Index Copernicus

Journal Citation Reports/Science Edition

Pubmed (NLM)

PubMed Central Selective Deposit Medicine & Health (NLM)

Science Citation Index Expanded (Clarivate Analytics)

Scopus (Elsevier)

Open access

Therapeutics and Clinical Risk Management is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.

Why choose open access?

  1. Increase the discoverability and readership of your article
  2. Make an impact and reach new readers, not just those with easy access to a research library
  3. Freely share your work with anyone, anywhere
  4. Comply with funding mandates and meet the requirements of your institution, employer or funder
  5. Rigorous peer review for every open access article

Article Publishing Charges (APC)

To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.

Use our APC finder to calculate your article publishing charge

News, offers and calls for papers

Ready to submit?

Start a new submission or continue a submission in progress

Go to submission site (link opens in a new window) Instructions for authors